COSCIENS Biopharma Bilan de santé

Santé financière contrôle des critères 4/6

COSCIENS Biopharma possède un total de capitaux propres de $20.0M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $43.8M et de $23.8M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$20.00m
Fonds propres	US$20.01m
Total du passif	US$23.76m
Total des actifs	US$43.77m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ET8 ( $28.2M ) dépassent ses passifs à court terme ( $8.2M ).

Passif à long terme: Les actifs à court terme de ET8 ( $28.2M ) dépassent ses passifs à long terme ( $15.6M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: ET8 est sans dette.

Réduire la dette: ET8 n'a actuellement aucune dette, mais nous ne pouvons pas comparer avec il y a 5 ans car nous n'avons pas de données pour cette période.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ET8 dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ET8 dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 24.1 % chaque année

COSCIENS Biopharma Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna Zentaris Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

The Nasdaq Stock Market LLC Grants an Additional 180 Calendar-Day Period Extension to Aeterna Zentaris to Regain Compliance with Minimum Bid Price Rule

Aeterna Receives Nasdaq Warning on Minimum Price

Recent updates

Third quarter 2024 earnings released: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)

COSCIENS Biopharma Inc. Announces Resignation of Carolyn Egbert from the Board of Directors

Cosciens Biopharma Inc. Announces Directorate Changes

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT- Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Second quarter 2024 earnings released: US$0.64 loss per share (vs US$2.07 loss in 2Q 2023)

Aeterna Zentaris Inc. Announces the Resignation of Peter G. Edwards as Director

Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction.

Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Aeterna Zentaris Inc. Provides an Update on Its Therapeutic and Diagnostic Development Pipeline Programs and Outlined Upcoming Key Milestones

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022

Aeterna Zentaris Inc. Achieves Proof-Of-Concept for the Treatment of NMOSD with AIM Biologicals Program

Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (Macimorelin) for Diagnosing Adult Growth Hormone Deficiency

Aeterna Zentaris Inc. Updates on Positive Pre-Clinical Results from Aim Biologicals Development Program for the Potential Treatment of Parkinson's Disease

First quarter 2022 earnings released: US$0.022 loss per share (vs US$0.015 loss in 1Q 2021)

Aeterna Zentaris Inc., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings released: US$0.073 loss per share (vs US$0.13 loss in FY 2020)

Aeterna Zentaris Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Third quarter 2021 earnings released: US$0.014 loss per share (vs US$0.02 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.15 loss in 2Q 2020)

Aeterna Zentaris Inc. Provides Update on Its Pre-Clinical and Clinical Development Programs

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

Aeterna Zentaris Inc. Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Independent Director has left the company

Aeterna Zentaris Announces the Selection of A Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.036 profit in 1Q 2020)

Full year 2020 earnings released: US$0.13 loss per share (vs US$0.34 loss in FY 2019)

Aeterna Zentaris Inc., Annual General Meeting, May 05, 2021

New 90-day high: €1.55

Aeterna Zentaris Inc. Enters into an Exclusive Option Agreement to Evaluate Preclinical Potential COVID-19 Vaccine Developed at the Julius-Maximilians-University Wuerzburg

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

The Nasdaq Stock Market LLC Grants an Additional 180 Calendar-Day Period Extension to Aeterna Zentaris to Regain Compliance with Minimum Bid Price Rule

New 90-day high: €0.60

New 90-day high: €0.37

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

New 90-day high: €0.35

Aeterna Zentaris Inc. Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

Third quarter 2020 earnings released: US$0.02 loss per share

New 90-day low: €0.28

The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc

New 90-day low: €0.28

Aeterna Zentaris Inc. Announces Macimorelin Clinical Program Update

New 90-day low - €0.34

First half earnings released

Aeterna Zentaris Inc. has completed a Follow-on Equity Offering in the amount of $7.000001 million.

New 90-day low - €0.35

Aeterna Receives Nasdaq Warning on Minimum Price

Aeterna Zentaris Inc. has completed a Composite Units Offering in the amount of $11.999087 million.

Aeterna Zentaris Inc.(NasdaqCM:AEZS) dropped from Russell Microcap Value Index

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines